DeepMed Research

Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Clinical Trials

Natalizumab (Tysabri) Re-Initiation of Dosing

Phase 3

Terminated

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Natalizumab

First Posted Date: 2006-02-28

Last Posted Date: 2016-07-15

Lead Sponsor: Biogen

Target Recruit Count: 1094

Registration Number: NCT00297232

Locations: 🇬🇧
Research Site, Stoke on Trent, United Kingdom

Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2006-02-16

Last Posted Date: 2007-12-31

Lead Sponsor: Biogen

Target Recruit Count: 50

Registration Number: NCT00292422

Locations: 🇺🇸
Fiechtner Research Inc., Lansing, Michigan, United States
🇺🇸
Arthritis Consultants Inc., St. Louis, Missouri, United States
🇵🇱
Klinika Chorob Tkanki Lacznej-Instytut Reumatologiczny, Warsawa, Poland

and more 7 locations

A Serologic Study to Correlate Beta-IFN NAb Titers to Beta-IFN Induced Biomarker Response in Patients With Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2006-02-09

Last Posted Date: 2007-12-24

Lead Sponsor: Biogen

Target Recruit Count: 300

Registration Number: NCT00288990

Locations: 🇺🇸
The Baptist Hospital of East Tennessee, Knoxville, Tennessee, United States
🇺🇸
Neurology Center of Fairfax, Ltd., Fairfax, Virginia, United States
🇺🇸
The Multiple Sclerosis Center at the Ohio State University, Columbus, Ohio, United States

and more 25 locations

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Phase 4

Completed

Conditions: Crohn's Disease

First Posted Date: 2006-01-24

Last Posted Date: 2016-06-16

Lead Sponsor: Biogen

Target Recruit Count: 2000

Registration Number: NCT00280956

Locations: 🇺🇸
Performed only at CD251, CD301, CD303, CD306, and CD307 sites globally. No general public enrollment. The study is managed from the office of Elan Pharmaceuticals, Inc. in, San Diego, California, United States

Open-Label Natalizumab Safety Extension Study

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Natalizumab

First Posted Date: 2006-01-13

Last Posted Date: 2009-06-22

Lead Sponsor: Biogen

Target Recruit Count: 1615

Registration Number: NCT00276172

Locations: 🇺🇸
Performed at only C-1801, C-1802, and C-1803 sites globally. No general public enrollment. Biogen Idec is located in, Cambridge, Massachusetts, United States

Safety and Tolerability of Repeat Courses of IM Alefacept

Phase 3

Completed

Conditions: Chronic Plaque Psoriasis

First Posted Date: 2005-10-06

Last Posted Date: 2023-08-23

Lead Sponsor: Biogen

Target Recruit Count: 400

Registration Number: NCT00233662

Locations: 🇨🇦
Dermatrials Research, Hamilton, Ontario, Canada
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇫🇷
Hopital L'Archet II, Nice, France

and more 43 locations

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Completed

Conditions: Prenatal Exposure Delayed Effects
Multiple Sclerosis
Pregnancy

Interventions: Drug: BG9418 (interferon beta-1a)

First Posted Date: 2005-09-15

Last Posted Date: 2014-06-09

Lead Sponsor: Biogen

Target Recruit Count: 329

Registration Number: NCT00168714

Locations: 🇺🇸
Kendle, Wilmington, North Carolina, United States

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Phase 4

Completed

Conditions: Relapsing-remitting Multiple Sclerosis

Interventions: Drug: Interferon-beta-1a (Avonex) plus methylprednisolone

First Posted Date: 2005-09-15

Last Posted Date: 2013-09-16

Lead Sponsor: Biogen

Target Recruit Count: 345

Registration Number: NCT00168766

Locations: 🇨🇭
Kantonspital, St. Gallen, Switzerland
🇧🇪
CUB Hôpital Erasme, Bruxelles, Belgium
🇳🇱
Stichting MS Centrum, Nijemegen, Netherlands

and more 6 locations

Efficacy and Safety of BG00012 in MS

Phase 2

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2005-09-15

Last Posted Date: 2023-08-28

Lead Sponsor: Biogen

Target Recruit Count: 260

Registration Number: NCT00168701

Locations: 🇸🇪
MS Centrum, Molndal, Sweden
🇨🇿
Faculty Hospital, Hradec Kralove, Czechia
🇨🇿
General Teaching Hospital, Prague, Czechia

and more 28 locations

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Phase 3

Completed

Conditions: Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

First Posted Date: 2005-09-15

Last Posted Date: 2005-09-15

Lead Sponsor: Biogen

Target Recruit Count: 150

Registration Number: NCT00168740

Locations: 🇺🇸
Hoag Hospital, Newport Beach, California, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, United States

and more 28 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy